<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "zoledronic acid inj VIAL">
<dose><value>4</value>
<value>5</value>
</dose><route><value>IV</value>
</route><form><value>inj VIAL</value>
</form><drugname><value>zoledronic acid inj VIAL</value>
</drugname><strength><value>0.8 mg/mL</value>
</strength><frequency><value>ONCE</value>
</frequency><instruction></instruction><volume><value>5 mL</value>
</volume><units><value>mg</value>
</units><additionalnotes><value>Hypercalcemia, Bone metastases and osteolytic lesions (CrCl greater than 60mL/minute.). The benefits of bisphosphonate drugs in preventing fractures associated with osteoporosis outweigh the risk of an atypical femur fracture (Health Canada; December 19, 2011)</value>
<value>Osteoporosis in postmenopausal women, glucocorticoid-induced in men. Administered annually. The benefits of bisphosphonate drugs in preventing fractures associated with osteoporosis outweigh the risk of an atypical femur fracture (Health Canada; December 19, 2011)</value>
<value>Prevention of postmenopausal osteoporosis, Paget's disease. The benefits of bisphosphonate drugs in preventing fractures associated with osteoporosis outweigh the risk of an atypical femur fracture (Health Canada; December 19, 2011)</value>
</additionalnotes><population><value>ADULT</value>
</population><indicationprn></indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3606</value>
</backgroundinformation><prninformation></prninformation><ahsformularystatus><value>Formulary with Restrictions.</value>
</ahsformularystatus><ahfsname><value>Bone Resorption Inhibitors</value>
</ahfsname><highalert></highalert><maximumprndose></maximumprndose><din><value>02401606</value>
</din><type><value>Medication/IV Therapy</value>
</type></drug>